| GROSICKI, Sebastian, Maryana SIMONOVA, Ivan SPICKA, Luděk POUR, Iryrna KRIACHOK, Maria GAVRIATOPOULOU, Halyna PYLYPENKO, Holger W AUNER, Xavier LELEU, Vadim DORONIN, Ganna USENKO, Nizar J BAHLIS, Roman HAJEK, Reuben BENJAMIN, Tuphan K DOLAI, Dinesh K SINHA, Christopher P VENNER, Mamta GARG, Mercedes GIRONELLA, Artur JURCZYSZYN, Pawel ROBAK, Monica GALLI, Craig WALLINGTON-BEDDOE, Atanas RADINOFF, Galina SALOGUB, DON, STEVENS, Supratik BASU, Anna M LIBERATI, Hang QUACH, Vesselina S GORANOVA-MARINOVA, Jelena BILA, Eirini KATODRITOU, Hanna OLIYNYK, Sybiryna KORENKOVA, Jeevan KUMAR, Sundar JAGANNATH, Phillipe MOREAU, Moshe LEVY, Darrell WHITE, Moshe E GATT, Thierry FACON, Maria V MATEOS, Michele CAVO, Donna REECE, Larry D Anderson JR, Jean-Richard SAINT-MARTIN, Jacqueline JEHA, ANITA, JOSHI, Yi CHAI, Lingling LI, Vishnuvardhan PEDDAGALI, Melina ARAZY, Jatin SHAH, Sharon SHACHAM, Michael G KAUFFMAN, MELETIOS, DIMOPOULOS, Paul G RICHARDSON a Sosana DELIMPASI. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. New York: Elsevier, 2020, roč. 396, č. 10262, s. 1563-1573. ISSN 0140-6736. Dostupné z: https://dx.doi.org/10.1016/S0140-6736(20)32292-3. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1775058,
author = {Grosicki, Sebastian and Simonova, Maryana and Spicka, Ivan and Pour, Luděk and Kriachok, Iryrna and Gavriatopoulou, Maria and Pylypenko, Halyna and Auner, Holger W and Leleu, Xavier and Doronin, Vadim and Usenko, Ganna and Bahlis, Nizar J and Hajek, Roman and Benjamin, Reuben and Dolai, Tuphan K and Sinha, Dinesh K and Venner, Christopher P and Garg, Mamta and Gironella, Mercedes and Jurczyszyn, Artur and Robak, Pawel and Galli, Monica and WallingtonandBeddoe, Craig and Radinoff, Atanas and Salogub, Galina and Don, and Stevens, and Basu, Supratik and Liberati, Anna M and Quach, Hang and GoranovaandMarinova, Vesselina S and Bila, Jelena and Katodritou, Eirini and Oliynyk, Hanna and Korenkova, Sybiryna and Kumar, Jeevan and Jagannath, Sundar and Moreau, Phillipe and Levy, Moshe and White, Darrell and Gatt, Moshe E and Facon, Thierry and Mateos, Maria V and Cavo, Michele and Reece, Donna and Jr, Larry D Anderson and SaintandMartin, JeanandRichard and Jeha, Jacqueline and Anita, and Joshi, and Chai, Yi and Li, Lingling and Peddagali, Vishnuvardhan and Arazy, Melina and Shah, Jatin and Shacham, Sharon and Kauffman, Michael G and Meletios, and Dimopoulos, and Richardson, Paul G and Delimpasi, Sosana},
article_location = {New York},
article_number = {10262},
doi = {http://dx.doi.org/10.1016/S0140-6736(20)32292-3},
issn = {0140-6736},
journal = {Lancet},
note = {Bez afiliace k MU.},
title = {Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial},
url = {https://www.sciencedirect.com/science/article/pii/S0140673620322923?via%3Dihub},
volume = {396},
year = {2020}
}
TY - JOUR
ID - 1775058
AU - Grosicki, Sebastian - Simonova, Maryana - Spicka, Ivan - Pour, Luděk - Kriachok, Iryrna - Gavriatopoulou, Maria - Pylypenko, Halyna - Auner, Holger W - Leleu, Xavier - Doronin, Vadim - Usenko, Ganna - Bahlis, Nizar J - Hajek, Roman - Benjamin, Reuben - Dolai, Tuphan K - Sinha, Dinesh K - Venner, Christopher P - Garg, Mamta - Gironella, Mercedes - Jurczyszyn, Artur - Robak, Pawel - Galli, Monica - Wallington-Beddoe, Craig - Radinoff, Atanas - Salogub, Galina - Don,
AU - Stevens,
AU - Basu, Supratik - Liberati, Anna M - Quach, Hang - Goranova-Marinova, Vesselina S - Bila, Jelena - Katodritou, Eirini - Oliynyk, Hanna - Korenkova, Sybiryna - Kumar, Jeevan - Jagannath, Sundar - Moreau, Phillipe - Levy, Moshe - White, Darrell - Gatt, Moshe E - Facon, Thierry - Mateos, Maria V - Cavo, Michele - Reece, Donna - Jr, Larry D Anderson - Saint-Martin, Jean-Richard - Jeha, Jacqueline - Anita,
AU - Joshi,
AU - Chai, Yi - Li, Lingling - Peddagali, Vishnuvardhan - Arazy, Melina - Shah, Jatin - Shacham, Sharon - Kauffman, Michael G - Meletios,
AU - Dimopoulos,
AU - Richardson, Paul G - Delimpasi, Sosana
PY - 2020
TI - Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
JF - Lancet
VL - 396
IS - 10262
SP - 1563-1573
EP - 1563-1573
PB - Elsevier
SN - 01406736
N1 - Bez afiliace k MU.
UR - https://www.sciencedirect.com/science/article/pii/S0140673620322923?via%3Dihub
N2 - Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor with bortezomib (a proteasome inhibitor) and dexamethasone induced high response rates with low rates of peripheral neuropathy, the main dose-limiting toxicity of bortezomib. We aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortezomib and dexamethasone in patients with previously treated multiple myeloma.
ER -
GROSICKI, Sebastian, Maryana SIMONOVA, Ivan SPICKA, Luděk POUR, Iryrna KRIACHOK, Maria GAVRIATOPOULOU, Halyna PYLYPENKO, Holger W AUNER, Xavier LELEU, Vadim DORONIN, Ganna USENKO, Nizar J BAHLIS, Roman HAJEK, Reuben BENJAMIN, Tuphan K DOLAI, Dinesh K SINHA, Christopher P VENNER, Mamta GARG, Mercedes GIRONELLA, Artur JURCZYSZYN, Pawel ROBAK, Monica GALLI, Craig WALLINGTON-BEDDOE, Atanas RADINOFF, Galina SALOGUB, DON, STEVENS, Supratik BASU, Anna M LIBERATI, Hang QUACH, Vesselina S GORANOVA-MARINOVA, Jelena BILA, Eirini KATODRITOU, Hanna OLIYNYK, Sybiryna KORENKOVA, Jeevan KUMAR, Sundar JAGANNATH, Phillipe MOREAU, Moshe LEVY, Darrell WHITE, Moshe E GATT, Thierry FACON, Maria V MATEOS, Michele CAVO, Donna REECE, Larry D Anderson JR, Jean-Richard SAINT-MARTIN, Jacqueline JEHA, ANITA, JOSHI, Yi CHAI, Lingling LI, Vishnuvardhan PEDDAGALI, Melina ARAZY, Jatin SHAH, Sharon SHACHAM, Michael G KAUFFMAN, MELETIOS, DIMOPOULOS, Paul G RICHARDSON a Sosana DELIMPASI. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. \textit{Lancet}. New York: Elsevier, 2020, roč.~396, č.~10262, s.~1563-1573. ISSN~0140-6736. Dostupné z: https://dx.doi.org/10.1016/S0140-6736(20)32292-3.
|
